Value-Based Care in Cardiometabolic Health Dec 2012, Vol 1, No 3
CABG Surgery Outcomes Superior to PCI and Cost-Effective in Patients with Diabetes and Multivessel CAD
Los Angeles, CA—The outcomes of coronary artery bypass graft (CABG) surgery are superior to those of percutaneous coronary intervention (PCI) in patients with diabetes and multivessel coronary artery disease (CAD). The better outcomes with CABG were achieved with a small increase in costs over 5 years compared with PCI, making CABG highly cost-effective in this population.
Obesity has reached epidemic proportions in the United States.1 Obesity, which is defined as a body mass index (BMI) of ≥30 kg/m2, affects an estimated 78.1 million Americans—more than 35% of all men and women.2,3 Moreover, more than 34% of adults aged ≥20 years are overweight, which is defined as a BMI of ≥25 kg/m2.3
Los Angeles, CA—An over-the-counter probiotic that reduces total and low-density lipoprotein cholesterol (LDL-C) levels in adults with moderate hypercholesterolemia has also been shown to lower cholesteryl ester saturated fatty acids, according to data presented at the American Heart Association 2012 Scientific Sessions.
Boston, MA—The amount and the type of omega-3 fatty acids are important for triglyceride lowering. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are distinct omega-3 polyunsaturated fatty acids, but only EPA has been shown to lower triglyceride levels, without increasing low-density lipoprotein cholesterol (LDL-C) in patients with very high triglycerides levels, said Harold Bays, MD, Medical Director and President, Louisville Metabolic and Atherosclerosis Research Center, KY, at the 2012 Cardiometabolic Health Congress.
Munich, Germany—New insights into blood pressure (BP) measurement, prognostic markers, and renal denervation come from a range of hypertension studies presented at the 2012 Congress of the European Society of Cardiology (ESC). Roland E. Schmieder, MD, Professor of Internal Medicine, Nephrology, and Hypertension, University of Erlangen, and Head of the Clinical Research Unit of Hypertension and Vascular Medicine, University Hospital Erlangen-Nürnberg, Germany, presented a tour of these studies.
Munich, Germany—Substantial reductions, by as much as 66%, in the risk of developing hypertension were found in people who adopted healthy lifestyle behaviors in a large prospective population-based cohort study in Finland, the results of which were presented by Pekka Jousilahti, MD, PhD, Research Professor from National Institute for Health and Welfare, Helsinki, Finland, at the 2012 European Society of Cardiology Congress.
Munich, Germany—Dual antiplatelet therapy with an anticoagulant plus clopidogrel was safe and effective at 1 year in patients with atrial fibrillation (AF) or mechanical valves who underwent a percutaneous coronary intervention (PCI), with less bleeding compared with the current guideline-recommended approach of triple therapy that includes aspirin.
Boston, MA—Optimal cardiovascular (CV) risk reduction in patients with diabetes must be multifactorial, stated James R. Gavin III, MD, PhD, Clinical Professor of Medicine, Emory University, Atlanta, GA, at the 2012 Cardiometabolic Health Congress.
A great deal is known about CV disease (CVD) in diabetes, yet its prevention remains a paradox. No matter how well its risks are mitigated, the rates of CVD in the presence of diabetes remain higher than in its absence “in ways that simply make no sense,” Dr Gavin said.
Munich, Germany—The risk of cardiovascular (CV) and all-cause death is nearly 3 times higher in persons with normal weight who nevertheless have excess belly fat than in people who are overweight or obese with a high waist-to-hip ratio (WHR), according to new data presented by Karine Sahakyan, MD, PhD, MPH, a cardiologist at the Mayo Clinic, Rochester, MN, at the 2012 European Society of Cardiology Congress.
Munich, Germany—A total of 16 novel classes of drugs are under development for the management of lipoprotein metabolism toward the prevention of cardiovascular disease (CVD), according to John J.P. Kastelein, MD, PhD, Academic Medical Center, University of Amsterdam, the Netherlands. Dr Kastelein reviewed several of these approaches at the 2012 European Society of Cardiology (ESC) Congress.
Page 1 of 3
Results 1 - 10 of 24
Results 1 - 10 of 24